Literature DB >> 6348429

Carnitine metabolism and deficiency syndromes.

C J Rebouche, A G Engel.   

Abstract

L-Carnitine is an essential cofactor in transfer of long-chain fatty acids across the inner mitochondrial membrane. L-Carnitine is present in living systems in free form and as short-chain and long-chain fatty acylcarnitine esters. In recent years, several clinical syndromes due to or associated with carnitine deficiency have been described. They include 2 primary types--systemic and muscle (or myopathic) carnitine deficiency--and at least 15 syndromes in which carnitine deficiency seems to be secondary to genetic defects of intermediary metabolism or to other conditions. Possible beneficial effects of exogenous carnitine in ischemic heart disease have been the focus of intensive research in recent years. Free carnitine and esterified carnitine are measured by a sensitive enzymatic-radiochemical method. In some cases, the diagnosis of carnitine deficiency can be made by assay of total (free plus esterified) carnitine in plasma or serum. Proper diagnosis, however, often depends on determination of total carnitine in skeletal muscle or liver (or both). Since the first clinical description of carnitine deficiency in 1973, considerable progress has been made in defining and classifying the carnitine deficiency syndromes. Recent efforts in basic and clinical research have provided important clues about the molecular causes of these syndromes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6348429

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  29 in total

Review 1.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

2.  Genetic deficiency of short-chain acyl-coenzyme A dehydrogenase in cultured fibroblasts from a patient with muscle carnitine deficiency and severe skeletal muscle weakness.

Authors:  P M Coates; D E Hale; G Finocchiaro; K Tanaka; S C Winter
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

3.  The importance of recognizing secondary carnitine deficiency in organic acidaemias: case report in glutaric acidaemia type II.

Authors:  H Mandel; D Africk; M Blitzer; E Shapira
Journal:  J Inherit Metab Dis       Date:  1988       Impact factor: 4.982

4.  Muscle carnitine deficiency presenting as familial fatal cardiomyopathy.

Authors:  A A Colin; M Jaffe; Y Shapira; Z Ne'eman; A Gutman; S Korman
Journal:  Arch Dis Child       Date:  1987-11       Impact factor: 3.791

5.  Kinetic compartmental analysis of carnitine metabolism in the human carnitine deficiency syndromes. Evidence for alterations in tissue carnitine transport.

Authors:  C J Rebouche; A G Engel
Journal:  J Clin Invest       Date:  1984-03       Impact factor: 14.808

6.  Role of carnitine in disease.

Authors:  Judith L Flanagan; Peter A Simmons; Joseph Vehige; Mark Dp Willcox; Qian Garrett
Journal:  Nutr Metab (Lond)       Date:  2010-04-16       Impact factor: 4.169

Review 7.  Treatment of the chronic fatigue syndrome. A review and practical guide.

Authors:  E Blondel-Hill; S D Shafran
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 8.  l-Carnitine. A preliminary review of its pharmacokinetics, and its therapeutic use in ischaemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism.

Authors:  K L Goa; R N Brogden
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

9.  Carnitine and physical exercise.

Authors:  O J Heinonen
Journal:  Sports Med       Date:  1996-08       Impact factor: 11.136

10.  L-carnitine enhances excretion of propionyl coenzyme A as propionylcarnitine in propionic acidemia.

Authors:  C R Roe; D S Millington; D A Maltby; T P Bohan; C L Hoppel
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.